Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LRX712 · 2 trials · 2 indications
Magnetic resonance images (MRI) were obtained from the target knee to visualize and quantify changes in the volume of cartilage in the index region. The index region was defined as the combination of the femoral medial anterior (FMA), central (FMC) and posterior (FMP) cartilage subregions in the knee. Change from baseline in cartilage volume was analyzed using the mixed effects model for repeated measures (MMRM). The model included baseline, treatment, timepoint and treatment-timepoints as fixed effects, and participant as random effect. Missing data was assumed to be Missing at Random (MAR).
To evaluate Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) of LRX712 after a single i.a. injection in osteoarthritic patients
| Arm | Type | Description |
|---|---|---|
| LRX712 15 mg | EXPERIMENTAL | LRX712 15 mg was administered intra-articularly (i.a.) every four weeks, for a total of three administrations. |
| LRX712 25 mg | EXPERIMENTAL | LRX712 25 mg was administered i.a. every four weeks, for a total of three administrations. |
| LRX712 75 mg | EXPERIMENTAL | LRX712 75 mg was administered i.a. every four weeks, for a total of three administrations. |
| Placebo | PLACEBO_COMPARATOR | Placebo was administered i.a. every four weeks, for a total of three administrations. |
| LRX712 | EXPERIMENTAL | LRX712 given intra-articularly |
| Name | Type | Description |
|---|---|---|
| LRX712 | DRUG | LRX712 intra-articular injections |
| Placebo | OTHER | Placebo intra-articular injections |
Inclusion Criteria: Written informed consent must be obtained before any assessment is performed. To be eligible for inclusion in this study patients must meet all of the following criteria: * Patient must have a BMI between 18 -35 kg/m2 * Patient must have symptomatic knee osteoarthritis predomi...
LRX712 is an investigational small molecule being developed for osteoarthritis (OA), specifically for patients with moderate knee osteoarthritis aged 30 to 65 years. It is administered via intra-articular injection and is currently in clinical development, with studies completed in Phase 1 and Phase 2.
The molecular target of LRX712 is not disclosed in available information. It is a small molecule being studied for its safety, tolerability, and preliminary efficacy in knee osteoarthritis, but its specific mechanism of action has not been publicly detailed.
LRX712 is being developed by Novartis AG, a multinational pharmaceutical company listed on the New York Stock Exchange under the ticker symbol NVS. Novartis is conducting clinical trials to evaluate the drug's safety and efficacy in patients with knee osteoarthritis.
LRX712 has completed Phase 1 and Phase 2 clinical trials. The Phase 2 study, NCT04097379, evaluated safety, tolerability, and preliminary efficacy of multiple intra-articular injections in patients with knee OA. The drug is not approved and remains investigational.
LRX712 has been studied in two completed trials: NCT03355196, a Phase 1 first-in-human study in osteoarthritic patients, and NCT04097379, a Phase 2 study of multiple intra-articular injections in knee OA patients. Both trials were conducted in the Netherlands.
No alternative names for LRX712 have been reported. It is identified solely by its code name LRX712 in clinical trial registries and by its developer, Novartis AG.